# WHO Recommends New Ebola Vaccines for Clinical Trials in DRC Two new vaccine candidates will undergo testing to combat the Bundibugyo Ebola virus outbreak. - **Source:** [Premium Times Nigeria](https://www.premiumtimesng.com) - **Published:** 2026-11-06 - **Topic:** [health](https://brifing.si/c/health) - **Original article:** - **On Brifing:** https://brifing.si/s/10f3949e-c7f7-4320-92e0-be07af3c4863 ## New Vaccine Candidates Approved The World Health Organization has officially recommended two additional vaccine candidates for clinical evaluation in the Democratic Republic of the Congo. These vaccines, ChAdOx1 and mRNA-1469, specifically target the Bundibugyo virus. This development marks the first time these specific candidates will be tested during an active outbreak of the disease. ## Collaborative Scientific Effort The trial is led by the Institut National de Recherche Biomédicale in the DRC, with significant support from international partners. Key collaborators include the University of Antwerp, Médecins Sans Frontières, and the Africa Centres for Disease Control and Prevention. This partnership ensures that research meets rigorous scientific and ethical standards throughout. ## The Tumaini Trial Strategy The Tumaini trial utilizes a ring-vaccination approach, focusing on individuals who have had contact with confirmed Bundibugyo virus patients. This methodology mirrors strategies successfully employed during the West African Ebola outbreak. Currently, four vaccination rings are established, with preparations underway to expand to additional contacts of those infected or deceased. ## Vaccine Development Background The rapid advancement of these candidates was made possible through strategic investments from the Coalition for Epidemic Preparedness Innovations. The University of Oxford developed ChAdOx1 in partnership with the Serum Institute of India, while Moderna developed the mRNA-1469 candidate. These efforts aim to strengthen existing control measures against the virus. ## Parallel Treatment Research Beyond vaccines, the WHO-sponsored PARTNERS trial is evaluating potential treatments for confirmed patients. Researchers are assessing the efficacy of monoclonal antibody MBP134, the antiviral drug remdesivir, and their combinations. Additionally, the drug maftivimab will soon be integrated into the study, alongside a separate investigation into obeldevisir for post-exposure prevention purposes. ## Expected Research Timelines While vaccines are essential tools, the WHO emphasizes that they are not a standalone solution for ending outbreaks. Initial findings from the ongoing treatment trials are expected within the coming months. Conversely, the comprehensive results from the vaccine trials are not anticipated until early 2027, providing a long-term outlook. ## Operational Support Framework The WHO is supporting this research through its Health Emergencies Programme and Research and Development Blueprint. This involvement provides critical technical advice, research protocols, and operational coordination. By managing these complex trials, the organization aims to generate vital evidence that could save lives and improve future responses to viral outbreaks. ## Significance of Clinical Data The data gathered from these trials will be instrumental in refining public health strategies against the Bundibugyo virus. By evaluating both existing vaccines like Ervebo and new candidates, health officials hope to establish a robust defense. The collective contributions of participants and researchers remain central to advancing global medical knowledge. ## Sources covering this story - https://www.premiumtimesng.com/news/top-news/923199-who-recommends-two-new-ebola-vaccines-for-clinical-trials-as-drc-battles-bundibugyo-outbreak.html — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._